The story of Viagra, originally marketed by copyright, presents a intricate case study for investors considering the healthcare sector. Although its groundbreaking success and generation of billions in sales, the exclusivity end has opened the floodgates for competing medications, significantly diminishing profit prospects . This shift raises conce